Mesdopetam-PPI Composition for Fast GERD Symptom Relief
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for gastrointestinal disorders such as GERD have limitations including slow onset of action, side effects, and non-compliance due to adverse reactions, necessitating the development of novel therapeutic options that address gastric motility and acid secretion effectively.
Innovation Solution
A composition comprising Mesdopetam, which stimulates gastric motility via dopamine D2/D3 and Alpha-1 adrenergic receptor inhibition, combined with proton pump inhibitors (PPIs) that irreversibly block the H+K+ ATPase enzyme to prevent gastric acid secretion, offering a fixed dose combination or separate administration.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional treatments (H2 blockers, metoclopramide, levosulpiride) are used to manage GERD and gastrointestinal symptoms, then acid secretion is reduced or motility is improved, but side effects increase and compliance decreases
Solution Approach 1:
The patent changes the pharmacological parameters by using a novel compound (mesdopetam) with a different mechanism of action that selectively targets dopamine D2/D3 receptors and alpha-1 adrenergic receptors, achieving therapeutic efficacy with reduced side effects compared to conventional treatments
Solution Approach 2:
The patent combines mesdopetam with proton pump inhibitors in a fixed dose combination formulation, creating a composite therapeutic agent that addresses both motility and acid secretion issues simultaneously, improving overall therapeutic efficacy while managing side effects
2Reliability
If proton pump inhibitors are used to suppress acid production, then acid secretion is effectively blocked, but onset of action is slow
Solution Approach 1:
The patent merges mesdopetam (which acts rapidly on dopamine and adrenergic receptors to improve motility) with proton pump inhibitors in a fixed dose combination, allowing the rapid-acting motility component to compensate for the slow onset of acid suppression, thereby reducing overall time to symptom relief
Solution Approach 2:
Mesdopetam provides preliminary improvement in gastric motility and emptying before the full acid suppression effect of the PPI kicks in, addressing symptoms earlier in the treatment timeline
3Productivity
If metoclopramide is used as a prokinetic agent, then gastric motility is improved, but extrapyramidal side effects occur
Solution Approach 1:
The patent changes the pharmacological target from conventional dopamine D2 antagonists (metoclopramide) to a novel compound with selective D2/D3 and alpha-1 adrenergic receptor activity, improving gastric motility while avoiding the extrapyramidal side effects associated with metoclopramide
Solution Approach 2:
The patent employs a novel compound (mesdopetam) that appears to have a more favorable safety profile and shorter duration of adverse effects compared to conventional prokinetics, effectively replacing older, more problematic agents
4Productivity
If levosulpiride is used as a motility agent, then gastric emptying is improved, but gynecomastia occurs
Solution Approach 1:
The patent changes the pharmacological mechanism by using mesdopetam with selective dopamine D2/D3 and alpha-1 adrenergic receptor antagonism, achieving improved gastric emptying while avoiding the hormonal side effects (gynecomastia) associated with levosulpiride
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The combination provides rapid and effective relief of gastrointestinal symptoms by enhancing gastric motility and reducing acid secretion, addressing the limitations of existing therapies with improved efficacy and reduced side effects.
Implementation Method 1
Mesdopetam stimulates gastric motility via inhibition of Dopamine D2/D3 receptors and Alpha-1 adrenergic receptors
Implementation Method 2
proton pump inhibitors (PPIs) that irreversibly block the H+K+ ATPase enzyme to prevent gastric acid secretion
Data Source
AI summary
The present invention relates to a composition comprising Mesdopetam alone or in combination with proton pump inhibitor which can be administered either separately i.e. by co-administration or in a fixed dose combination (FDC) in the treatment of gastrointestinal and related disorders. The present invention provides use of mesdopetam in the manufacture of a medicament for the treatment of gastrointestinal disorders in a subject in need thereof wherein the medicament is to be administered to the subject. The present invention also relates to a method of treating gastrointestinal diseases in a subject in need thereof comprising administering to the subject mesdopetam and pharmaceutical composition.